ES2052071T3 - Cuerpo oclusivo para administrar una sustancia fisiologicamente activa. - Google Patents

Cuerpo oclusivo para administrar una sustancia fisiologicamente activa.

Info

Publication number
ES2052071T3
ES2052071T3 ES89903777T ES89903777T ES2052071T3 ES 2052071 T3 ES2052071 T3 ES 2052071T3 ES 89903777 T ES89903777 T ES 89903777T ES 89903777 T ES89903777 T ES 89903777T ES 2052071 T3 ES2052071 T3 ES 2052071T3
Authority
ES
Spain
Prior art keywords
active substance
physiologically active
cavity
microporous membrane
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89903777T
Other languages
English (en)
Spanish (es)
Inventor
John Mark Tucker
Mark Rupert Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2052071T3 publication Critical patent/ES2052071T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
ES89903777T 1988-02-23 1989-02-23 Cuerpo oclusivo para administrar una sustancia fisiologicamente activa. Expired - Lifetime ES2052071T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888804164A GB8804164D0 (en) 1988-02-23 1988-02-23 Bandage for administering physiologically active compound

Publications (1)

Publication Number Publication Date
ES2052071T3 true ES2052071T3 (es) 1994-07-01

Family

ID=10632193

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89903777T Expired - Lifetime ES2052071T3 (es) 1988-02-23 1989-02-23 Cuerpo oclusivo para administrar una sustancia fisiologicamente activa.

Country Status (11)

Country Link
US (1) US5254346A (index.php)
EP (2) EP0508979B1 (index.php)
JP (1) JP2716231B2 (index.php)
KR (1) KR970009723B1 (index.php)
AU (1) AU618085B2 (index.php)
DE (1) DE68915291T2 (index.php)
ES (1) ES2052071T3 (index.php)
GB (1) GB8804164D0 (index.php)
IN (1) IN172748B (index.php)
WO (1) WO1989007959A1 (index.php)
ZA (1) ZA891403B (index.php)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
JPH02149514A (ja) * 1988-04-06 1990-06-08 Nitto Denko Corp 医薬部材
DE69108136T2 (de) * 1990-08-03 1995-11-02 Terumo Corp Wundabdeckmaterial.
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
CH686816A5 (de) * 1992-02-04 1996-07-15 Asulab Ag Einrichtung zur Abgabe eines Arzneimittels.
US6071896A (en) * 1992-06-16 2000-06-06 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
DE9219105U1 (de) * 1992-10-31 1998-03-05 Klocke Verpackungs-Service GmbH, 76356 Weingarten Behälter zur Aufnahme von aromatischen Substanzen
ES2199954T3 (es) * 1992-11-09 2004-03-01 Neurogesx, Inc. Administracion transdermica de cetorolac.
FR2709670B1 (fr) * 1993-09-10 1995-10-20 Asulab Sa Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse.
EP0743842B1 (en) * 1994-03-07 2003-08-13 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6119036A (en) * 1997-03-26 2000-09-12 The Board Of Regents Of The University Of Oklahoma Iontophoretic transdermal delivery device
US5919476A (en) * 1997-09-29 1999-07-06 Pmt Corporation Reinforced gel sheeting for scar treatment
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
ES2226394T3 (es) * 1998-05-22 2005-03-16 Novosis Ag Sistemas transdermales que contienen substancia activa que se libera de forma controlada en el tiempo.
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2445086C (en) 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
DE60239528D1 (de) 2001-05-01 2011-05-05 Corium International Redwood City Zweiphasige, wasserabsorbierende bioadhäsive zusammenstezung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1546184A4 (en) * 2002-07-16 2006-08-23 Univ South Florida HUMAN IMMUNOSUPPRESSIVE PROTEIN
EP2130541A3 (en) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2506615A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
CA2729967C (en) * 2002-12-13 2018-01-16 Scholl's Wellness Company Llc Use of a transdermal or transmucosal ingredient delivery device
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
EP1620112A4 (en) * 2003-04-17 2007-04-25 Univ Columbia DESMOGLEIN 4 IS A NEW GENUS INVOLVED IN HAIR GROWTH
EP1648363B1 (en) 2003-07-03 2019-03-06 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
MXPA06002609A (es) * 2003-09-08 2006-06-05 Pfizer Health Ab Formulaciones de nicotina y uso de las mismas.
KR20070007299A (ko) 2004-01-30 2007-01-15 코리움 인터네셔널, 인크. 활성제의 전달을 위한 급속 용해 필름
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
EP1747022A4 (en) 2004-04-23 2010-03-31 Univ Columbia INHIBITION OF HAIRLESS PROTEIN MRNA
US20050249791A1 (en) * 2004-05-07 2005-11-10 3M Innovative Properties Company Antimicrobial articles
GB2414461B (en) * 2004-05-24 2007-09-12 Mark Rupert Tucker Form-fill-seal process
KR20070048229A (ko) 2004-08-05 2007-05-08 코리움 인터네셔널, 인크. 접착제 조성물
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
ATE551995T1 (de) 2004-10-21 2012-04-15 Durect Corp Transdermale abgabesysteme
GB2421431B (en) * 2004-12-24 2007-10-10 Aquasol Ltd Dosing systems
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
EP1965776A1 (en) * 2005-12-08 2008-09-10 Fertin Pharma Low flexural strength transdermal tobacco alkaloid patch
US20090246264A1 (en) * 2005-12-08 2009-10-01 Fertin Pharma Transdermal Tobacco Alkaloid Patch
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5386180B2 (ja) * 2006-02-28 2014-01-15 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 真皮細胞のコンパクト凝集のための方法
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
EP3067044B1 (en) 2006-07-21 2019-03-27 BioDelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
WO2008049123A2 (en) 2006-10-19 2008-04-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
CA2673137C (en) 2006-11-21 2015-02-10 Rigel Pharmaceuticals, Inc. Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
WO2008145119A1 (en) * 2007-05-31 2008-12-04 Fertin Pharma A/S Transdermal tobacco alkaloid reservoir patch
WO2009027850A2 (en) * 2007-06-06 2009-03-05 Multi-Tech Specialty Chemicals Co., Ltd. Process for the preparation of xanthophyll crystals
US8293786B2 (en) * 2007-07-30 2012-10-23 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
PE20100235A1 (es) * 2008-08-22 2010-03-29 Sanofi Aventis [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
EP2382210B1 (en) 2008-12-30 2017-03-01 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
WO2010083035A2 (en) 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
PT2389372E (pt) 2009-01-23 2016-01-07 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
BR112012000254A2 (pt) 2009-07-08 2016-02-16 Dermira Canada Inc análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
US20110034415A1 (en) * 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
US20110038904A1 (en) * 2009-08-17 2011-02-17 Silipos Inc. Gel Product
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
WO2011078984A1 (en) 2009-12-23 2011-06-30 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
PT2516418E (pt) 2009-12-23 2014-07-18 Sanofi Sa Profármacos de [4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1- il]-(1h-pirrolo-piridin-il)-metanonas e sua síntese
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US20110288103A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, compositions, and methods comprising 1,3,4-oxadiazole derivatives
CN103068390A (zh) 2010-04-20 2013-04-24 寰宇一家健康研究所 包含哒嗪磺酰胺衍生物的化合物、组合物和方法
CA2792950C (en) 2010-04-24 2014-02-11 Viamet Pharmaceuticals, Inc. 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
US20120208855A1 (en) 2010-07-12 2012-08-16 Sanofi Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
PL2598500T3 (pl) 2010-07-28 2021-11-29 Rigel Pharmaceuticals, Inc. Kompozycje i sposoby hamowania szlaku JAK
EP2632903A4 (en) 2010-10-28 2014-11-26 Viamet Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
KR20180039185A (ko) 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
CA2820718A1 (en) 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2820425A1 (en) 2010-12-20 2012-06-28 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
WO2012116254A2 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
EP2683410A2 (en) 2011-03-08 2014-01-15 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
CN105884743B (zh) 2011-06-19 2019-08-06 威尔金制药(Nc)有限公司 金属酶抑制剂化合物
KR101912850B1 (ko) 2011-06-19 2018-10-30 비아멧 파마슈티컬즈(엔씨), 인코포레이티드 금속효소 억제제 화합물
WO2012177728A1 (en) 2011-06-23 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
AU2012296346A1 (en) 2011-08-18 2014-04-03 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
MX2014002535A (es) 2011-09-02 2015-07-17 Univ Columbia Inhibidores de camkii, ip3r, calcineurina, p38 y mk2/3 para tratar las alteraciones metabolicas de la obesidad.
JP6085613B2 (ja) 2011-12-11 2017-02-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害薬化合物
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
ES2774267T3 (es) 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
NZ629898A (en) 2012-03-23 2016-04-29 Oxigene Inc Compositions and methods for inhibition of cathepsins
EP2830662B1 (en) 2012-03-29 2018-08-29 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2014116973A1 (en) 2013-01-25 2014-07-31 Rigel Pharmaceuticals, Inc. Compounds and methods for treating inflammatory bowel diseases
CA2907152A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2015089310A1 (en) * 2013-12-11 2015-06-18 Atkinson Oscar Occlusive skin covering
US20150174386A1 (en) * 2013-12-19 2015-06-25 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
WO2015134920A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
JP2017514790A (ja) 2014-03-19 2017-06-08 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
LT3271347T (lt) 2015-03-19 2022-10-10 Mycovia Pharmaceuticals, Inc. Priešgrybeliniai junginiai ir jų gamybos būdai
ES2811136T3 (es) 2015-08-04 2021-03-10 Rigel Pharmaceuticals Inc Compuestos de benzazol y métodos para obtener y usar los compuestos
MX391538B (es) 2015-09-18 2025-03-21 Mycovia Pharmaceuticals Inc Proceso de compuesto antifungico.
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
EP3397629B1 (en) 2015-12-30 2023-04-19 NQP 1598, Ltd. Metalloenzyme inhibitor compounds
JP6960937B2 (ja) 2016-03-08 2021-11-05 リビング プルーフ インコーポレイテッド 長期持続性化粧品組成物
JP7065840B2 (ja) 2016-06-27 2022-05-12 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４－ジアミノ－ピリミジン化合物ならびに該化合物の作製法および使用法
US10981928B2 (en) 2016-06-29 2021-04-20 Halo Life Science, Llc Methods of making low odor choline salts of an organic compound
WO2018089199A1 (en) 2016-10-26 2018-05-17 Rigel Pharmaceuticals, Inc. Oxazole derivatives for use as irak inhibitors and method for their preparation
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
CN110691598A (zh) 2016-12-29 2020-01-14 赛列尼蒂治疗(百慕大)有限公司 金属酶抑制剂化合物
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
GB201708579D0 (en) * 2017-05-30 2017-07-12 Univ Of Wolverhampton Science Park Ltd Wound dressing
CN111032642B (zh) 2017-06-29 2023-07-18 里格尔药品股份有限公司 激酶抑制剂及制造和使用方法
GB2561262B (en) * 2017-07-13 2019-03-20 Dentmed Ltd A targeted drug delivery pad
US10987300B2 (en) 2017-09-13 2021-04-27 Living Proof, Inc. Long lasting cosmetic compositions
CA3074845A1 (en) 2017-09-13 2019-03-21 Living Proof, Inc. Color protectant compositions
US12029805B2 (en) 2017-11-20 2024-07-09 Living Proof, Inc. Properties for achieving long-lasting cosmetic performance
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
EP3784711A1 (en) 2018-04-27 2021-03-03 Living Proof, Inc. Long lasting cosmetic compositions
US10815206B2 (en) 2018-05-03 2020-10-27 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
CA3099018A1 (en) 2018-05-03 2019-11-07 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
CN114269383A (zh) 2019-01-08 2022-04-01 菲斯生物制药公司 金属酶抑制剂化合物
US11090346B2 (en) 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
CN114698370A (zh) 2019-08-08 2022-07-01 里格尔药品股份有限公司 用于治疗细胞因子释放综合征的化合物和方法
CN114286679A (zh) 2019-08-14 2022-04-05 里格尔药品股份有限公司 阻断或改善细胞因子释放综合征的方法
EP4003990A1 (en) 2019-08-30 2022-06-01 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
KR102785137B1 (ko) 2019-09-06 2025-03-25 리겔 파마슈티칼스, 인크. Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
US11564930B2 (en) 2019-09-06 2023-01-31 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
EP4055021B1 (en) 2019-11-07 2025-10-08 Rigel Pharmaceuticals, Inc. Heterocyclic rip1 inhibitory compounds
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
WO2023136749A1 (ru) * 2022-01-11 2023-07-20 Павел Владимирович КОРЧАГИН Система и способ обеспечения безопасности для держателей банковских карт
EP4496794A1 (en) 2022-03-23 2025-01-29 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
US12459941B2 (en) 2022-03-31 2025-11-04 Rigel Pharmaceuticals, Inc. Tricyclic IRAK inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
ZA761193B (en) * 1975-03-19 1977-02-23 Procter & Gamble Controlled release articles
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
EP0184910B1 (en) * 1984-11-15 1992-09-30 Hercon Laboratories Corporation Device for controlled release drug delivery
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
DE3587616D1 (de) * 1984-12-22 1993-11-11 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
GB8512358D0 (en) * 1985-05-16 1985-06-19 Euro Celtique Sa Transdermal delivery system

Also Published As

Publication number Publication date
EP0508979A1 (en) 1992-10-21
GB8804164D0 (en) 1988-03-23
KR900700153A (ko) 1990-08-11
IN172748B (index.php) 1993-11-20
JP2716231B2 (ja) 1998-02-18
WO1989007959A1 (en) 1989-09-08
ZA891403B (en) 1989-11-29
DE68915291D1 (de) 1994-06-16
EP0336543A1 (en) 1989-10-11
DE68915291T2 (de) 1994-09-01
JPH03503636A (ja) 1991-08-15
US5254346A (en) 1993-10-19
AU3289589A (en) 1989-09-22
EP0508979B1 (en) 1994-05-11
AU618085B2 (en) 1991-12-12
KR970009723B1 (ko) 1997-06-17

Similar Documents

Publication Publication Date Title
ES2052071T3 (es) Cuerpo oclusivo para administrar una sustancia fisiologicamente activa.
DE69102140D1 (de) Wirkstoffabgabevorrichtung die ein hydrophobisches mittel enthält.
YU165789A (en) Use of asymmetrical membranes in agents for active substances controlled releasing
BE905933A (fr) Emplatres transdermiques et dermiques comportant plusieurs subdivisions.
ES2042700T3 (es) Composiciones farmaceuticas con liberacion controlada, y metodo para su preparacion.
DE3265043D1 (en) Applicators for pharmaceutically active agents, their preparation and use
DE3770550D1 (de) Tragbare osmotische einrichtung zur infusion mit geregelter freigabe.
DK156289A (da) Farmaceutisk praeparat indrettet til kontrolleret afgivelse af aktiv bestanddel
DE69629628D1 (de) Schnittstelle für Iontophorese
KR950007808A (ko) 약물투여용 의료용구
KR890701164A (ko) 피부침투성 치료 시스템
ES8801123A1 (es) Procedimiento para producir un comprimido de dispensacion de un principio biologicamente activo.
IL39474A (en) Device for the application of active ingredients
NO892985L (no) Nytt, fast og poroest enhetselement omfattende mikropartikler og/eller nanopartikler og fremgangsmaate for fremstilling derav.
ES2055677T1 (es) Procedimiento de obtencion de una composicion para el tratamiento de la disfuncion erectil.
SE7714066L (sv) Tillforselenhet for biologiskt aktiva emnen
ES2002840A6 (es) Un dispositivo para distribuir sustancias volatiles
BR8404607A (pt) Dispositivo para a liberacao controlada de um material ativo em um meio aquoso e pilula,pastilha,granulo,implante ou bolo alimentar de ruminantes
IE882898L (en) Solubility modulated drug delivery device
DK324687A (da) Transdermalt farmeceutisk praeparat
ES2058627T3 (es) Sistema terapeutico para la administracion retardada y dirigida a traves de la piel o de las mucosas de sustancias activas.
NO894467L (no) Reservoar for styrt frigjoering av aktive substanser, anordning som inneholder den, fremgangsmaate for aa fremstille den, og bruk av anordningen.
YU22894A (sh) Sistemi za kontrolisano davanje pilokarpina
JPS56100716A (en) Drug administration member
ES2017282A6 (es) Aposito para aplicaciones de substancias activas por via transcutanea con fines terapeuticos o cosmeticos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 508979

Country of ref document: ES